Monitor the say-on-pay vote outcome closely — if approval drops below 70%, it signals significant shareholder discontent with the pay-for-performance disconnect. Also watch for any shareholder proposals at future meetings given the widening net losses and declining TSR.
Price Chart
Executive Summary
XBiotech's 2026 definitive proxy statement schedules a virtual annual meeting for November 24, 2026, with three proposals: election of five incumbent directors (including founder John Simard as Chairman), ratification of Whitley Penn LLP as auditor, and an advisory say-on-pay vote. The filing reveals that former CEO John Simard received total compensation of $30,134,204 in FY2025, including $17.3 million in severance and $8.5 million in bonuses, while the company reported a net loss of $45.54 million and a TSR of negative 41.56% for the same period. The CEO-to-median-employee pay ratio stands at 345:1, and the company's net loss has widened each year from 2023 to 2025.
Key Facts
- Former CEO John Simard received total compensation of $30,134,204 in FY2025, including $17,341,326 in severance and $8,530,442 in bonuses.
- The company reported a net loss of $45.54 million in FY2025, widening from $38.53 million in FY2024 and $24.56 million in FY2023.
- Total shareholder return (TSR) for FY2025 was negative 41.56%, compared to 2.25% in FY2024 and 13.96% in FY2023.
- CEO-to-median-employee pay ratio is 345:1, with median employee total compensation of $87,096.
- The company had 30,487,731 shares of common stock outstanding as of September 25, 2026.
- Founder John Simard beneficially owns 17.5% of outstanding shares (5,671,650 shares).
- Thomas Gut (Lindenberg Family Office) is the largest external shareholder at 12.8%.
- All five director nominees are incumbents; no contested elections or shareholder proposals are on the ballot.
- The Audit Committee has selected Whitley Penn LLP as independent auditor for FY2026; audit fees were $323,000 in FY2025.
- A previously disclosed $10 million convertible loan from John Simard to the company was fully repaid and terminated on January 31, 2025.
Financial Impact
Former CEO received $30.1M total compensation (including $17.3M severance and $8.5M bonuses) while the company posted a $45.5M net loss and negative 41.6% TSR in FY2025.
Risk Factors
- Shareholder dissatisfaction with executive compensation given the 345:1 pay ratio and negative TSR.
- Continued net losses and cash burn without a clear path to profitability.
- Founder John Simard remains Chairman and holds 17.5% of shares, maintaining significant influence despite CEO retirement.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001171843-26-006362 |
| Document: 0001171843-26-006362-index-headers.html | 0001171843-26-006362 |
| Document: 0001171843-26-006362-index.html | 0001171843-26-006362 |
| Document: 0001171843-26-006362.txt | 0001171843-26-006362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.92 | awaiting T+5 | — | $1.93 (+0.52%) |
Oct 2, 2026 24d ago | DEF 14A | $2.19 $2.29 | ▼ −4.57% | ▼ −3.41% | $1.93 (+11.87%) |
Apr 29, 2026 25w ago | 10-K/A | $2.52 $2.55 | ▲ +1.19% | ▼ −1.92% | $1.93 (−23.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers